vs

Side-by-side financial comparison of BIOMARIN PHARMACEUTICAL INC (BMRN) and Skyward Specialty Insurance Group, Inc. (SKWD). Click either name above to swap in a different company.

BIOMARIN PHARMACEUTICAL INC is the larger business by last-quarter revenue ($766.2M vs $475.9M, roughly 1.6× Skyward Specialty Insurance Group, Inc.). BIOMARIN PHARMACEUTICAL INC runs the higher net margin — 13.8% vs 10.5%, a 3.4% gap on every dollar of revenue. On growth, Skyward Specialty Insurance Group, Inc. posted the faster year-over-year revenue change (44.8% vs 3.0%). Over the past eight quarters, Skyward Specialty Insurance Group, Inc.'s revenue compounded faster (30.4% CAGR vs 3.7%).

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).

Skyward Specialty Insurance Group, Inc. is a specialty property and casualty insurance provider offering tailored coverage solutions including commercial auto, general liability, professional indemnity, and specialty property policies. It primarily serves small-to-medium enterprises and niche industry segments across the United States, focusing on underwriting complex, hard-to-place risks for underserved client groups.

BMRN vs SKWD — Head-to-Head

Bigger by revenue
BMRN
BMRN
1.6× larger
BMRN
$766.2M
$475.9M
SKWD
Growing faster (revenue YoY)
SKWD
SKWD
+41.8% gap
SKWD
44.8%
3.0%
BMRN
Higher net margin
BMRN
BMRN
3.4% more per $
BMRN
13.8%
10.5%
SKWD
Faster 2-yr revenue CAGR
SKWD
SKWD
Annualised
SKWD
30.4%
3.7%
BMRN

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BMRN
BMRN
SKWD
SKWD
Revenue
$766.2M
$475.9M
Net Profit
$106.0M
$49.7M
Gross Margin
74.6%
Operating Margin
16.9%
14.9%
Net Margin
13.8%
10.5%
Revenue YoY
3.0%
44.8%
Net Profit YoY
EPS (diluted)
$0.54
$1.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMRN
BMRN
SKWD
SKWD
Q1 26
$766.2M
$475.9M
Q4 25
$874.6M
$385.6M
Q3 25
$776.1M
$382.5M
Q2 25
$825.4M
$319.9M
Q1 25
$745.1M
$328.5M
Q4 24
$747.3M
$304.4M
Q3 24
$745.7M
$300.9M
Q2 24
$712.0M
$279.9M
Net Profit
BMRN
BMRN
SKWD
SKWD
Q1 26
$106.0M
$49.7M
Q4 25
$-46.6M
$43.2M
Q3 25
$-30.7M
$45.9M
Q2 25
$240.5M
$38.8M
Q1 25
$185.7M
$42.1M
Q4 24
$124.9M
$14.4M
Q3 24
$106.1M
$36.7M
Q2 24
$107.2M
$31.0M
Gross Margin
BMRN
BMRN
SKWD
SKWD
Q1 26
74.6%
Q4 25
68.5%
Q3 25
82.0%
Q2 25
81.8%
Q1 25
79.7%
Q4 24
81.8%
Q3 24
74.7%
Q2 24
81.7%
Operating Margin
BMRN
BMRN
SKWD
SKWD
Q1 26
16.9%
14.9%
Q4 25
-5.1%
14.2%
Q3 25
-6.0%
15.8%
Q2 25
33.5%
15.6%
Q1 25
30.0%
15.7%
Q4 24
21.6%
6.1%
Q3 24
15.3%
15.6%
Q2 24
16.9%
14.4%
Net Margin
BMRN
BMRN
SKWD
SKWD
Q1 26
13.8%
10.5%
Q4 25
-5.3%
11.2%
Q3 25
-4.0%
12.0%
Q2 25
29.1%
12.1%
Q1 25
24.9%
12.8%
Q4 24
16.7%
4.7%
Q3 24
14.2%
12.2%
Q2 24
15.1%
11.1%
EPS (diluted)
BMRN
BMRN
SKWD
SKWD
Q1 26
$0.54
$1.09
Q4 25
$-0.22
$1.03
Q3 25
$-0.16
$1.10
Q2 25
$1.23
$0.93
Q1 25
$0.95
$1.01
Q4 24
$0.65
$0.33
Q3 24
$0.55
$0.89
Q2 24
$0.55
$0.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMRN
BMRN
SKWD
SKWD
Cash + ST InvestmentsLiquidity on hand
$2.2B
$4.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$6.2B
$1.2B
Total Assets
$8.6B
$6.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMRN
BMRN
SKWD
SKWD
Q1 26
$2.2B
$4.1M
Q4 25
$1.3B
$168.5M
Q3 25
$1.3B
$160.1M
Q2 25
$1.2B
$136.6M
Q1 25
$1.0B
$112.9M
Q4 24
$942.8M
$121.6M
Q3 24
$675.4M
$105.6M
Q2 24
$972.1M
$73.0M
Stockholders' Equity
BMRN
BMRN
SKWD
SKWD
Q1 26
$6.2B
$1.2B
Q4 25
$6.1B
$1.0B
Q3 25
$6.1B
$961.4M
Q2 25
$6.0B
$899.9M
Q1 25
$5.8B
$850.7M
Q4 24
$5.7B
$794.0M
Q3 24
$5.4B
$797.5M
Q2 24
$5.3B
$723.6M
Total Assets
BMRN
BMRN
SKWD
SKWD
Q1 26
$8.6B
$6.5B
Q4 25
$7.6B
$4.8B
Q3 25
$7.6B
$4.6B
Q2 25
$7.5B
$4.3B
Q1 25
$7.1B
$4.0B
Q4 24
$7.0B
$3.7B
Q3 24
$6.9B
$3.6B
Q2 24
$7.1B
$3.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMRN
BMRN
SKWD
SKWD
Operating Cash FlowLast quarter
$220.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
2.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMRN
BMRN
SKWD
SKWD
Q1 26
$220.7M
Q4 25
$99.6M
$408.1M
Q3 25
$368.7M
$171.4M
Q2 25
$185.3M
$88.2M
Q1 25
$174.4M
$96.8M
Q4 24
$185.6M
$305.1M
Q3 24
$221.5M
$168.0M
Q2 24
$118.8M
$21.0M
Free Cash Flow
BMRN
BMRN
SKWD
SKWD
Q1 26
Q4 25
$58.9M
$402.6M
Q3 25
$340.2M
$168.9M
Q2 25
$168.2M
$87.1M
Q1 25
$157.6M
$96.6M
Q4 24
$166.1M
$300.9M
Q3 24
$203.0M
$167.6M
Q2 24
$97.4M
$18.4M
FCF Margin
BMRN
BMRN
SKWD
SKWD
Q1 26
Q4 25
6.7%
104.4%
Q3 25
43.8%
44.2%
Q2 25
20.4%
27.2%
Q1 25
21.2%
29.4%
Q4 24
22.2%
98.8%
Q3 24
27.2%
55.7%
Q2 24
13.7%
6.6%
Capex Intensity
BMRN
BMRN
SKWD
SKWD
Q1 26
Q4 25
4.7%
1.4%
Q3 25
3.7%
0.6%
Q2 25
2.1%
0.3%
Q1 25
2.3%
0.1%
Q4 24
2.6%
1.4%
Q3 24
2.5%
0.1%
Q2 24
3.0%
0.9%
Cash Conversion
BMRN
BMRN
SKWD
SKWD
Q1 26
2.08×
Q4 25
9.44×
Q3 25
3.73×
Q2 25
0.77×
2.27×
Q1 25
0.94×
2.30×
Q4 24
1.49×
21.18×
Q3 24
2.09×
4.58×
Q2 24
1.11×
0.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons